Journal of Cancer and Tumor Research

Popular Keywords

Cancer Biology & Tumorigenesis

Tumor microenvironment

Cancer stem cells

Oncogenes and tumor suppressor genes

Epigenetics in cancer

Metastasis and invasion mechanisms

Does Peritoneal Carcinomatosis Owing To Uterine Cancer Require Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy?

Correspondence to Author: ÖzgüSl Düzgün, and Mufewrat Kalin

300 George St, Ste 120, New Haven.

Introduction: One of the most prevalent pelvic tumors in women is uterine carcinoma (UC). In females, the lifetime risk for UC is approximately 4% [1]. Women between the ages of 60 and 70 are typically affected. After receiving surgery, chemotherapy, radiation therapy, and hormone therapy, UC has a favorable prognosis; additionally, UC accounts for just 2% of cancerrelated deaths [2]. Although they only account for 15% of newly diagnosed cases, advanced stage UC is associated with a bad prognosis. Females with distant (20–25%) or local (49– 66%) peritoneal metastases have lower 5-year survival rates, with a median survival of less than a year [3,4].According to the guidelines, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can be used to treat selected patients with ovarian and colon cancers who have low peritoneal carcinomatosis index (PCI) scores, as well as cases of pseudomyxoma peritonei originating from the appendix without extra-abdominal metastases.

Keywords:uterine cancer; peritoneal carcinomatosis; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy.

Citation:

ÖzgüSl Düzgün. Does Peritoneal Carcinomatosis Owing To Uterine Cancer Require Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy?. Journal Of Cancer And Tumor Research 2025.